Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease
J N Caviness1, J G Hentz, V G Evidente
1Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, USA. jcaviness@mayo.edu
Parkinsonism & Related Disorders
|March 10, 2007
Summary
Quantitative electroencephalography (EEG) measures show potential as biomarkers for cognitive decline in Parkinson's disease (PD). These EEG biomarkers can track early and late stages of cognitive impairment in PD patients.
Area of Science:
- Neuroscience
- Neurology
- Biomarkers
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder associated with progressive cognitive decline.
- Identifying reliable biomarkers for cognitive impairment in PD is crucial for early detection and treatment monitoring.
- Current diagnostic methods may not fully capture the spectrum of cognitive changes in PD.
Purpose of the Study:
- To establish quantitative electroencephalography (EEG) measures as reliable biomarkers for early and late cognitive decline in Parkinson's disease (PD).
- To differentiate cognitive states in PD using electrophysiological data.
- To explore the potential of EEG in evaluating PD treatments targeting cognitive function.
Main Methods:
- Studied Parkinson's disease (PD) subjects categorized into cognitively normal (PD-CogNL), mild cognitive impairment (PD-MCI), and dementia (PD-D) groups.
- Correlated cognitive status and neuropsychological test results with background rhythm and EEG power across five frequency bands.
- Utilized quantitative electroencephalography (qEEG) for detailed electrophysiological analysis.
Main Results:
- Global quantitative EEG measures demonstrated potential as biomarkers for cognitive deterioration in PD.
- Distinct EEG characteristics were observed across different cognitive groups (PD-CogNL, PD-MCI, PD-D).
- PD-MCI subjects exhibited intermediate quantitative EEG features between PD-CogNL and PD-D groups, suggesting an electrophysiological continuum.
Conclusions:
- Quantitative EEG measures hold promise as biomarkers for assessing cognitive decline in Parkinson's disease.
- EEG can aid in the study of both early and advanced cognitive impairment in PD.
- These findings support the use of EEG for monitoring treatment efficacy in PD cognitive dysfunction.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...